Adtalem Global Education (NYSE:CVSA) SVP Sells $1,221,393.45 in Stock

Adtalem Global Education Inc. (NYSE:CVSA) SVP Douglas Beck sold 9,615 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $127.03, for a total transaction of $1,221,393.45. Following the completion of the sale, the senior vice president owned 38,159 shares in the company, valued at approximately $4,847,337.77. This trade represents a 20.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adtalem Global Education Trading Down 1.7%

Shares of CVSA opened at $126.55 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.70 and a current ratio of 0.70. The stock has a market cap of $4.31 billion, a price-to-earnings ratio of 19.71, a P/E/G ratio of 1.07 and a beta of 0.63. The firm has a 50-day moving average of $113.50. Adtalem Global Education Inc. has a 12-month low of $86.97 and a 12-month high of $156.26.

Adtalem Global Education (NYSE:CVSA) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.73 by $0.25. The company had revenue of $487.03 million for the quarter. Adtalem Global Education had a net margin of 12.26% and a return on equity of 20.19%. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter last year, the company earned $1.92 earnings per share. Adtalem Global Education has set its FY 2026 guidance at 7.950-8.150 EPS. Equities research analysts forecast that Adtalem Global Education Inc. will post 8.03 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CVSA. Zacks Research lowered shares of Adtalem Global Education from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 25th. Barrington Research reiterated an “outperform” rating and set a $170.00 price target on shares of Adtalem Global Education in a research note on Friday, April 17th. Weiss Ratings began coverage on shares of Adtalem Global Education in a research note on Wednesday, February 25th. They set a “hold (c+)” rating on the stock. Truist Financial boosted their price target on shares of Adtalem Global Education from $130.00 to $140.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Wall Street Zen downgraded Adtalem Global Education from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $155.00.

Adtalem Global Education Company Profile

Adtalem Global Education (NYSE: CVSA) is a provider of higher education and workforce solutions focused primarily on programs that prepare students for professional careers in healthcare, medicine, veterinary medicine and related fields. The company operates campus-based and online degree programs, continuing professional education, clinical training and exam-preparation offerings designed to support students seeking licensure and employment in regulated professions.

Adtalem’s portfolio includes institution brands that deliver undergraduate, graduate and professional training across nursing, medicine, veterinary medicine and allied health disciplines.